InvestorsHub Logo
Followers 3
Posts 16
Boards Moderated 0
Alias Born 06/13/2014

Re: None

Tuesday, 09/01/2015 7:28:36 PM

Tuesday, September 01, 2015 7:28:36 PM

Post# of 20
Today Nevro submitted and posted a link to their preliminary response to the patent trial and appeals board with reference to the Boston Scientific Corporation challenge to the key Nevro patent.
See http://www.nevro.com/press-release/?r=US&prid=5aa76c3f-164d-4b00-8def-f9ad36ba33b2. I personally, though not a lawyer, was impressed by the strength of the rebuttal.
On another note, I have heard that the first few patients in my state that have received the preliminary trial for effectiveness of the Senza have faired well, and are going to move on to permanent implants. A number of advisory services have not been favorably viewing Nevro, but IMO that is because they are looking at past performance and not considering the game change that FDA approval represents. Others that look at the whole picture, such as Zacks, are very high on NVRO (Rank 1).
Long on NVRO, and added on the recent dip. The sparseness of contributions to this board is an indication that the stock is flying under the radar. I was clued in when the Senza was recommended for my spouse.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVRO News